EUVIMEDEUVIMED entdecken
Fallbericht

Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma

Mayuko Yamamoto iD, Kimiko Nakajima, Mayuko Matsuda, Aya Takahashi, Kozo Nakai

Pediatric Dermatology · 2025

DOI: 10.1111/pde.15844 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Mayuko Yamamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Scleroderma, Localized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is the first report of pediatric linear scleroderma successfully treated with the topical Janus kinase (JAK) inhibitor delgocitinib. JAK inhibitors targeting the JAK/STAT pathway have been used to treat various immune‐mediated diseases. In both in vitro and in vivo, JAK inhibitors also block the transforming growth factor (TGF)‐β‐mediated effects that contribute to skin sclerosis. In the present case, the histological findings of inflammation and fibrosis were considered as conditions that would benefit from the anti‐inflammatory and antifibrotic effects of the JAK inhibitor, delgocitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsScleroderma, LocalizedChildHumansAdministration, TopicalSkinPyrroles

Stichwörter der Autor:innen

delgocitiniblinear sclerodermapediatrictopical JAK inhibitor

Substanzen

delgocitinibJanus Kinase InhibitorsPyrroles

Autor:innen und Institutionen

  • Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
  • Department of Dermatology, Graduate School of Medical, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

ORCID-Profile: Mayuko Yamamoto

Zitieren

APA

Yamamoto, M., Nakajima, K., Matsuda, M., Takahashi, A., & Nakai, K. (2025). Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma. Pediatric Dermatology. https://doi.org/10.1111/pde.15844

Vancouver

Yamamoto M, Nakajima K, Matsuda M, Takahashi A, Nakai K. Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma. Pediatric Dermatology. 2025. doi:10.1111/pde.15844

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Mayuko and Nakajima, Kimiko and Matsuda, Mayuko and Takahashi, Aya and Nakai, Kozo},
  title = {Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma},
  journal = {Pediatric Dermatology},
  year = {2025},
  doi = {10.1111/pde.15844}
}
Kostenlos starten →